Document is current
Any future updates will be listed below
-
Authors
Thomsen, Andreas Vinther
Ashina, Håkan
Al-Khazali, Haidar M.
Rose, Kathrine
Christensen, Rune Häckert
Amin, Faisal Mohammad
Ashina, Messoud
-
Funding
Funding for this research was provided by:
Lundbeck Foundation (R310-2018-3711)
- License Information
-
More Information
Article History
Received: 1 November 2023
Accepted: 16 January 2024
First Online: 13 February 2024
Declarations
:
: The study protocol received approval from the Health Research Ethics Committee of the Capital Region of Denmark, and all participants provided written informed consent before undergoing any study-related assessments or procedures.
: Not applicable.
: H.A. reports personal fees from Lundbeck and Teva, outside of the submitted work. H.M.A. reports personal fees from Pfizer, outside of the submitted work. F.M.A. reports personal fees from Eli Lilly, Lundbeck, Novartis, Teva, and Pfizer, outside of the submitted work. F.M.A. also serves on the editorial board of Cephalalgia, Cephalalgia Reports, Frontiers in Neurology, Frontiers in Pain Research, Headache Medicine, and The Journal of Headache and Pain. M.A. reports personal fees from AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer, and Teva, outside of the submitted work. M.A. also serves on the editorial board of Brain, Cephalalgia, and The Journal of Headache and Pain. A.V.T., K.R., and R.H.C. report no potential conflicts of interest.
